Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305910 · ClinicalTrials.gov registry record · Phase 1
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
A Phase 1 study of Diffuse Midline Glioma, H3 K27M-Mutant and Recurrent High Grade Glioma, sponsored by OX2 Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06305910: Recruiting Phase 1 study of Diffuse Midline Glioma, H3 K27M-Mutant and Recurrent High Grade Glioma, sponsored by OX2 Therapeutics.
NCT06305910 is a Phase 1 study of Diffuse Midline Glioma, H3 K27M-Mutant and Recurrent High Grade Glioma that is actively recruiting participants, run by OX2 Therapeutics. The registered enrollment target is 24 participants, below the 231-participant average among 11 other Diffuse Midline Glioma, H3 K27M-Mutant trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06305910, a Phase 1 study of Diffuse Midline Glioma, H3 K27M-Mutant and Recurrent High Grade Glioma, is actively recruiting participants, sponsored by OX2 Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults. The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation therapy for newly diagnosed Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG).
Primary Outcome
Maximum tolerated dose (MTD) of CD200AR-L when administered with imiquimod and GBM6-AD vaccine to treat High-Grade Glioma (HGG) and Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DMG/DIPG) in children and young adults.
Conditions Studied
Interventions
- DRUG Treatment with CD200AR-L
Study Locations (1)
Minnesota
- Children's Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 1 |
What NCT06305910 shows while recruiting
NCT06305910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 231-participant average among 11 other Diffuse Midline Glioma, H3 K27M-Mutant trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Diffuse Midline Glioma, H3 K27M-Mutant appearing as the primary indexed condition, and to 1 intervention - of which Treatment with CD200AR-L is the first listed.
NCT06305910 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06305910 about?
NCT06305910 is a clinical study titled "CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults". This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults. The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD20...
What is the current status of trial NCT06305910?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-03-15. Estimated completion is 2027-01-15.
What conditions does trial NCT06305910 study?
This clinical trial studies the following conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma.
What interventions are being tested in trial NCT06305910?
The interventions under investigation include: Treatment with CD200AR-L (DRUG).
Who is sponsoring clinical trial NCT06305910?
This trial is sponsored by OX2 Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06305910 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Midline Glioma, H3 K27M-Mutant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06305910's enrollment target sits among peer trials
24 9th of 11 higher than 3 of 11 other Diffuse Midline Glioma, H3 K27M-Mutant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Midline Glioma, H3 K27M-Mutant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
RECRUITING · Phase 1
-
FUS Etoposide for DMG
RECRUITING · Phase 1
-
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
-
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
RECRUITING · Phase 1
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI